Bayer is ready to spend money on more drug licensing agreements like last year’s deal with Loxo Oncology but its priority is to reduce debt after the takeover of Monsanto.
Source:: Reuters – Business News
Bayer is ready to spend money on more drug licensing agreements like last year’s deal with Loxo Oncology but its priority is to reduce debt after the takeover of Monsanto.
Source:: Reuters – Business News
Copyright 1997-2019 Wall Street Reporter / Octagon Media Corp.